Vallon Pharmaceuticals

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Vallon Pharmaceuticals is an emerging pharmaceutical company focused on the development of new medications to help patients with central nervous system (CNS) disorders. The company’s lead investigational product candidate is an abuse deterrent formulation of amphetamine immediate release (ADAIR) for the treatment of ADHD and Narcolepsy.

Vallon began conducting clinical trials of ADAIR in 2018 and expects to submit an NDA in 2021. ADAIR is partnered in Europe and we are seeking commercial partners for the US and RoW.

Vallon intends to develop multiple products using its patented abuse deterrent technology, including an abuse deterrent formulation of Ritalin.
Company Type:
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
ADAIR (Abuse Deterrent Amphetamine Immediate Release)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
CEO
Vallon Pharmaceuticals